SG Americas Securities’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

SG Americas Securities’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-96,238	Closed	-$4.62M	–	3977
2020 Q1	$4.62M	Buy	96,238 +87,394	+988%	+$4.07M	0.04%	412
2019 Q4	$415K	Sell	8,844 -60,785	-87%	-$2.69M	﹤0.01%	1926
2019 Q3	$1.65M	Buy	+69,629	New	+$2.06M	0.01%	1086
2019 Q2	–	Sell	-6,942	Closed	-$156K	–	3614
2019 Q1	$156K	Sell	6,942 -2,441	-26%	-$52.5K	﹤0.01%	2746
2018 Q4	$171K	Buy	+9,383	New	+$147K	﹤0.01%	2460

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

SG Americas Securities's RARX Position: Q2 2020 in Review

SG Americas Securities sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 96,238 shares — an estimated $4.62M sold.

SG Americas Securities first reported a position in RARX in Q4 2018 and held it in 5 quarters. The position peaked at $4.62M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

SG Americas Securities reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
SG Americas Securities sold 96,238 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $4.62M.
SG Americas Securities first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 5 quarters.
SG Americas Securities's Ra Pharmaceuticals, Inc. Common Stock position peaked at $4.62M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on SG Americas Securities's 13F filing for Q2 2020, filed 20 Jul 2020.